Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Crow's Feet Lines
NCT01776606Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2012
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daxibotulinumtoxinA in Crow's feet, sponsored by Revance Therapeutics. Started Dec 2012; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
Crow's feet
Beyond the preview
Go deeper on NCT01776606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01776606.